These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22200426)

  • 1. A nexus of progression of chronic kidney disease: tryptophan, profibrotic cytokines, and charcoal.
    Schulman G
    J Ren Nutr; 2012 Jan; 22(1):107-13. PubMed ID: 22200426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nexus of progression of chronic kidney disease: charcoal, tryptophan and profibrotic cytokines.
    Schulman G
    Blood Purif; 2006; 24(1):143-8. PubMed ID: 16361855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AST-120 ameliorates epithelial-to-mesenchymal transition and interstitial fibrosis in the kidneys of chronic kidney disease rats.
    Bolati D; Shimizu H; Niwa T
    J Ren Nutr; 2012 Jan; 22(1):176-80. PubMed ID: 22200438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoxyl sulfate is a nephro-vascular toxin.
    Niwa T
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S2-6. PubMed ID: 20797565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uremic toxicity of indoxyl sulfate.
    Niwa T
    Nagoya J Med Sci; 2010 Feb; 72(1-2):1-11. PubMed ID: 20229698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indoxyl sulfate induces nephrovascular senescence.
    Niwa T; Shimizu H
    J Ren Nutr; 2012 Jan; 22(1):102-6. PubMed ID: 22200425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure.
    Miyazaki T; Ise M; Hirata M; Endo K; Ito Y; Seo H; Niwa T
    Kidney Int Suppl; 1997 Dec; 63():S211-4. PubMed ID: 9407462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients.
    Niwa T; Tsukushi S; Ise M; Miyazaki T; Tsubakihara Y; Owada A; Shiigai T
    Miner Electrolyte Metab; 1997; 23(3-6):179-84. PubMed ID: 9387112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease.
    Yorioka N; Kiribayashi K; Naito T; Ogata S; Yokoyama Y; Kyuden Y; Ogawa T; Wada K; Hayashi K; Hirabayashi A
    J Nephrol; 2008; 21(2):213-20. PubMed ID: 18446716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120.
    Niwa T
    Ther Apher Dial; 2011 Apr; 15(2):120-4. PubMed ID: 21426500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of carbon adsorbent in the conservative management of chronic kidney disease.
    Niwa T
    Panminerva Med; 2017 Jun; 59(2):139-148. PubMed ID: 27990791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease.
    Fujii H; Nakai K; Fukagawa M
    Ther Apher Dial; 2011 Apr; 15(2):125-8. PubMed ID: 21426501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting protein-bound uremic toxins in chronic kidney disease.
    Niwa T
    Expert Opin Ther Targets; 2013 Nov; 17(11):1287-301. PubMed ID: 23941498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure.
    Iida S; Kohno K; Yoshimura J; Ueda S; Usui M; Miyazaki H; Nishida H; Tamaki K; Okuda S
    Clin Exp Nephrol; 2006 Dec; 10(4):262-7. PubMed ID: 17186330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
    Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
    Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive effects of an oral sorbent on nephropathy in rats.
    Aoyama I; Miyazaki T; Niwa T
    Miner Electrolyte Metab; 1999; 25(4-6):365-72. PubMed ID: 10681668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral carbonaceous absorbent modifies renal function of renal ablation model without affecting plasma renin-angiotensin system or protein intake.
    Horike K; Usami T; Kamiya Y; Kamiya T; Yoshida A; Itoh S; Yamato H; Ise M; Kimura G
    Clin Exp Nephrol; 2003 Jun; 7(2):120-4. PubMed ID: 14586730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress.
    Fujii H; Nishijima F; Goto S; Sugano M; Yamato H; Kitazawa R; Kitazawa S; Fukagawa M
    Nephrol Dial Transplant; 2009 Jul; 24(7):2089-95. PubMed ID: 19188341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure].
    Ciechanowicz A
    Ann Acad Med Stetin; 1999; Suppl 52():1-93. PubMed ID: 10589103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.